Fulcrum Therapeutics, INC Form 4 insider transactions

Curtis Gale Oltmans, Chief Legal Officer of Fulcrum Therapeutics, received stock options for 225,000 shares on January 24, 2025, vesting quarterly over four years.

Director Rachel King of Fulcrum Therapeutics acquired 60,000 stock options on November 12, 2024, which vest monthly until November 2027.

RA Capital Healthcare Fund exchanged 8,500,000 shares of Fulcrum Therapeutics common stock for an equal number of prefunded warrants.

Fulcrum Therapeutics CEO Alex Sapir exercised stock options to acquire 150,000 shares of common stock at $3.27 per share on July 3, 2024.

Director Alan Ezekowitz reports the acquisition of stock options in Fulcrum Therapeutics.

Director Robert J. Gould reports the acquisition of stock options for 30,000 shares of Fulcrum Therapeutics common stock.

Director Kate Haviland reports acquisition of 30,000 stock options in Fulcrum Therapeutics, Inc.

Director James Geraghty of Fulcrum Therapeutics, Inc. reports the acquisition of 30,000 stock options on June 17, 2024.

Director Katina Dorton reports the acquisition of stock options in Fulcrum Therapeutics, Inc.

Director James J. Collins of Fulcrum Therapeutics, Inc. reports the acquisition of 30,000 stock options on June 17, 2024.

Director Sonja Banks reports acquisition of 30,000 stock options in Fulcrum Therapeutics, Inc.

Director Colin Hill received stock options to purchase 60,000 shares of Fulcrum Therapeutics stock, vesting monthly until June 2027.

Gregory Tourangeau, Principal Accounting Officer of Fulcrum Therapeutics, sold 236 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Patrick Taylor Horn, Chief Medical Officer of Fulcrum Therapeutics, acquired 400,000 stock options on March 18, 2024.

Gregory Tourangeau, VP of Finance at Fulcrum Therapeutics, sold 4,884 shares of common stock at an average price of $11.7155 on March 8, 2024.

Alex Sapir, President & CEO of Fulcrum Therapeutics, recently purchased 43,360 shares of FULC stock at an average price of $11.3475 per share.